Evidence map›Paper›PMID 32182759›Full record

ArticleCells2020

Cross Interaction between M2 Muscarinic Receptor and Notch1/EGFR Pathway in Human Glioblastoma Cancer Stem Cells: Effects on Cell Cycle Progression and Survival.

Ilaria Cristofaro, Francesco Alessandrini, Zaira Spinello, Claudia Guerriero, Mario Fiore, Elisa Caffarelli, Pietro Laneve, Luciana Dini, Luciano Conti, Ada Maria Tata

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ilaria CristofaroDepartment of Biology and Biotechnologies Charles Darwin, Sapienza, University of Rome, 00185 Rome, Italy.
Francesco AlessandriniDepartment of Biology and Biotechnologies Charles Darwin, Sapienza, University of Rome, 00185 Rome, Italy.ORCID 0000-0002-8450-848X
Zaira SpinelloDepartment of Biology and Biotechnologies Charles Darwin, Sapienza, University of Rome, 00185 Rome, Italy.
Claudia GuerrieroDepartment of Biology and Biotechnologies Charles Darwin, Sapienza, University of Rome, 00185 Rome, Italy.
Mario FioreIBPM, Institute of Molecular Biology and Pathology, CNR, 00185 Rome, Italy.
Elisa CaffarelliIBPM, Institute of Molecular Biology and Pathology, CNR, 00185 Rome, Italy.
Pietro LaneveIBPM, Institute of Molecular Biology and Pathology, CNR, 00185 Rome, Italy.
Luciana DiniDepartment of Biology and Biotechnologies Charles Darwin, Sapienza, University of Rome, 00185 Rome, Italy.
Luciano ContiDepartment of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, 38123 Trento, Italy.ORCID 0000-0002-2050-9846
Ada Maria TataDepartment of Biology and Biotechnologies Charles Darwin, Sapienza, University of Rome, 00185 Rome, Italy.ORCID 0000-0003-4868-5435
Sapienza University of Rome · ITInstitute of Molecular Biology and Pathology · ITUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastomas (GBM) are the most aggressive form of primary brain tumors in humans. A key feature of malignant gliomas is their cellular heterogeneity. In particular, the presence of an undifferentiated cell population of defined Glioblastoma Stem cells (GSCs) was reported. Increased expression of anti-apoptotic and chemo-resistance genes in GCSs subpopulation favors their high resistance to a broad spectrum of drugs. Our previous studies showed the ability of M2 muscarinic receptors to negatively modulate the cell growth in GBM cell lines and in the GSCs. The aim of this study was to better characterize the inhibitory effects of M2 receptors on cell proliferation and survival in GSCs and investigate the molecular mechanisms underlying the M2-mediated cell proliferation arrest and decreased survival. Moreover, we also evaluated the ability of M2 receptors to interfere with Notch1 and EGFR pathways, whose activation promotes GSCs proliferation. Our data demonstrate that M2 receptors activation impairs cell cycle progression and survival in the primary GSC lines analyzed (GB7 and GB8). Moreover, we also demonstrated the ability of M2 receptor to inhibit Notch1 and EGFR expression, highlighting a molecular interaction between M2 receptor and the Notch-1/EGFR pathways also in GSCs.

Indexed as

Signal TransductionBrain NeoplasmsCell CycleCell DivisionCell Line, TumorCell ProliferationErbB ReceptorsGlioblastomaHumansNeoplastic Stem CellsReceptor, Muscarinic M2Receptor, Notch1EGFR protein, humanErbB ReceptorsNOTCH1 protein, humanReceptor, Muscarinic M2Receptor, Notch1apoptosiscancer stem cellscell cycleEGFRM2 muscarinic receptorsNotch

Identifiers

PMID32182759
PMCPMC7140674
OpenAlexW3009594297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.